Avicanna (TSE:AVCN) has released an update.
Avicanna Inc., a leader in cannabinoid-based biopharmaceuticals, successfully elected its management’s nominees as company directors and reaffirmed its auditor appointment during the Annual General Meeting. The company continues to progress in the medical cannabis industry with an expanding portfolio, including the RHO Phyto formulary and the MyMedi.ca care platform.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.